Home › Premarket Biotech Digest: Tracking Gilead HCV Sales, Shire-Baxalta Deal, AstraZeneca Deal
 

Keywords :   


Premarket Biotech Digest: Tracking Gilead HCV Sales, Shire-Baxalta Deal, AstraZeneca Deal

2015-12-17 17:08:44| Biotech - Topix.net

The current consensus forecast for fourth quarter HCV sales is $2.81 billion. In the third quarter, U.S. HCV sales had totaled $3.23 billion.

Tags: sales deal tracking digest

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »